Project Grant P50NS132955
Award Date
8/15/24
Completion Date
7/31/28
Dollars Obligated
$1.5M
Federal Agency
National Institute of Neurological Disorders and Stroke
Federal Grant Program
93.853
Assistance Type
Project Grant
Place of Performance
Florida, USA
Similar Awards
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training Program (CFDA 93.859) provides $434,750 to California State University San Marcos Corp to conduct research on the molecular mechanisms underlying myotonic dystrophy type 2 (DM2). The project aims to elucidate the causes of CCTG repeat instability and large-scale contractions in the CNBP gene, which are associated with DM2. Key objectives include...
Under a $1,525,000 Project Grant awarded by the Defense Health Agency (CFDA 12.420 - Military Medical Research and Development), the University of Florida's Division of Sponsored Research will conduct research to "UNDERSTANDING AND TARGETING COMMON MECHANISMS OF MYOTONIC DYSTROPHY TYPES 1AND 2 USING NOVEL REPEAT EXPANSION MOUSE MODELS." This 4-year research project, commencing on Sep 1, 2023, will advance the understanding and treatment of myotonic dystrophy, a genetic disorder that...
This $1,525,000 Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports foundational studies at the University of Florida to understand the phenotypic, region-specific, and cell-specific dysregulation in the central nervous system of individuals with myotonic dystrophy. The 4-year award, effective May 15, 2024, will enable the university to conduct innovative research to advance the understanding of this neurological...
The University of Florida (UF) received a $1,524,836 Project Grant award from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) to conduct research on understanding and targeting common mechanisms of myotonic dystrophy types 1 and 2 using novel repeat expansion mouse models. The grant, which began on September 1, 2023 and will continue through August 31, 2027, supports UF's cutting-edge biomedical research efforts to transform healthcare for Service...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, is providing $236,566.00 to the University of Alabama at Birmingham (UAB) to investigate the contribution of circadian rhythm disruption to Duchenne muscular dystrophy (DMD) disease pathology. The research aims to evaluate the role of dystrophin expression in the skeletal muscle and...
This $1,557,819 Project Grant award from the National Institute of Child Health and Human Development (CFDA 93.865 - Child Health and Human Development Extramural Research) supports muscular dystrophy research at the Research Institute at Nationwide Children's Hospital in Columbus, Ohio. The award funds three key research projects: Project 1 (PI: Paul Martin, PhD) aims to utilize a novel bicistronic AAV vector to both prevent muscle disease and build new muscle function in patients with limb...
This $110,000 Project Grant award from the National Center for Advancing Translational Sciences (NCATS) under CFDA 93.350 supports research by Greenstone Biosciences, Inc. to develop advanced drug discovery and development technologies for rare genetic disorders. The project aims to leverage induced pluripotent stem cell (iPSC) technology and artificial intelligence/machine learning (AI/ML) to accelerate and streamline the drug discovery process for myotonic dystrophy type 1 (DM1), a rare and...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will fund research to develop improved gene replacement and editing therapies for Duchenne muscular dystrophy (DMD). The total award amount is $671,240 and the project period runs from January 22, 2025 to December 31, 2029. The key research objectives are to: 1) Refine technologies for expressing...
This $692,292 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research at the Children's Research Institute to better understand the regulation of pediatric regenerative myogenesis and its implications for muscle disease. The project aims to investigate the interplay of immune and stromal factors in the muscle niche that...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $1,541,019 Cooperative Agreement under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program to The Trustees of the University of Pennsylvania. The award supports a comprehensive translational and clinical research program to develop a safe and effective gene therapy treatment for the ultra-rare subset of Duchenne muscular dystrophy (DMD) patients...